Garadacimab for hereditary angioedema prophylaxis in adolescents: efficacy and safety from the VANGUARD Phase 3 and 3b open-label extension trial (first interim analysis)

被引：0
|
作者：
Magerl, M. [1 ]
Saguer, I. Martinez [2 ]
Jacos, J. S. [3 ]
Li, H. [4 ]
Bernstein, J. A. [5 ]
Hsu, C. [6 ]
Sitz, K. V. [7 ]
Pragst, I. [8 ]
Feuersenger, H. [8 ]
Wieman, L. [9 ]
Pollen, M. [9 ]
Rese, A. [10 ]
机构：
[1] Charite, Fraunhofer Inst Translat Med & Pharmacol ITMP All, Berlin Inst Allergol, Berlin, Germany
[2] HZRM Haemophilia Ctr Rhein Main, Morfelden Walldorf, Germany
[3] Allergy Asthma Clin Res, Walnut Creek, CA USA
[4] Inst Asthma & Allergy, Chevy Chase, MD USA
[5] Univ Cincinnati, Dept Internal Med, Div Rheumatol Allergy & Immunol & Bernstein Clin, Res Ctr Cincinnati, Cincinnati, OH USA
[6] Res Solut Arizona PC, Litchfield Pk, AZ USA
[7] Little Rock Allergy & Asthma Clin, Little Rock, AR USA
[8] CSL Behring Innovat GmbH, Marburg, Germany
[9] CSL Behring, King Of Prussia, PA USA
[10] Barzilai Univ Hosp, Allergy Immunol Angioedema Ctr, Ashqelon, Israel
来源：
ALLERGOLOGIE | 2023年 / 46卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P8.12
引用
收藏
页码：562 / 562
页数：1
相关论文
共 50 条
  • [1] Garadacimab For Hereditary Angioedema Prophylaxis In Adolescents: Efficacy And Safety From The Phase 3 (VANGUARD) Study And Open-Label Extension (Second Interim Analysis)
    Jacobs, Joshua
    Magerl, Markus
    Martinez-Saguer, Inmaculada
    Li, Huamin
    Bernstein, Jonathan
    Hsu, Connie
    Sitz, Karl
    Wieman, Lolis
    Feuer-Senger, Henrike
    Pollen, Maressa
    Reshef, Avner
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB6 - AB6
  • [2] Garadacimab for hereditary angioedema prophylaxis: long term efficacy and safety from the Phase 3 VANGUARD trial and first interim analysis of the open-label extension trial
    Reshef, A.
    Magerl, M.
    Saguer, I. Martinez
    Bernstein, J. A.
    Farkas, H.
    Yang, W. H.
    Jacobs, J. S.
    Li, P. Hei
    Lumry, W. R.
    Aygoeren-Puersuen, E.
    Ohsawa, I.
    Katelaris, C.
    Longhurst, H.
    Hakl, R.
    Guilarte, M.
    Stroes, E. S. G.
    Feuersenger, H.
    Bica, M. A.
    Jacobs, I.
    Craig, T. J.
    ALLERGOLOGIE, 2023, 46 (08) : 561 - 562
  • [3] Garadacimab for hereditary angioedema prophylaxis: Efficacy and safety from a Phase 2 open-label extension trial
    Craig, T. J.
    Reshef, A.
    Lumry, W. R.
    Saguer, I. Martinez
    Jacobs, J. S.
    Yang, W. H.
    Aygoren-Pursun, E.
    Keith, P. K.
    Busse, P.
    Magerl, M.
    Feuersenger, H.
    Bica, M. A.
    Glassman, F.
    Pragst, I.
    Levy, D. S.
    ALLERGOLOGIE, 2023, 46 (08) : 560 - 561
  • [4] Integrated Safety And Efficacy Of Garadacimab For Hereditary Angioedema Prophylaxis Across 3 Clinical Trials: Phase 2, Pivotal Phase 3, And Open-Label Extension Studies
    Craig, Timothy
    Anderson, John
    Jacobs, Joshua
    Tachdjian, Raffi
    Farkas, Henriette
    Yang, William
    Ohsawa, Isao
    Pollen, Maressa
    Lawo, John-Philip
    Bica, Alex
    Jacobs, Iris
    Magerl, Markus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB256 - AB256
  • [5] Long-term efficacy and safety of subcutaneous garadacimab for prophylaxis of hereditary angioedema attacks: Results from a multicentre phase 3 study and open-label extension
    Magerl, M.
    Reshef, A.
    Farkas, H.
    Li, H. H.
    Jacobs, J. S.
    Bernstein, J.
    Yang, W.
    Stroes, E. S.
    Ohsawa, I.
    Tachdjian, R.
    Manning, M. E.
    Lumry, W. R.
    Saguer, I. Martinez
    Aygoeren-Puersuen, E.
    Ritchie, B.
    Sussman, G. L.
    Anderson, J.
    Kawahata, K.
    Suzuki, Y.
    Staubach, P.
    Treudler, R.
    Feuersenger, H.
    Jacobs, I.
    Craig, T. J.
    ALLERGY, 2023, 78 : 115 - 117
  • [6] Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study
    Reshef, Avner
    Hsu, Connie
    Katelaris, Constance H.
    Li, Philip H.
    Magerl, Markus
    Yamagami, Keiko
    Guilarte, Mar
    Keith, Paul K.
    Bernstein, Jonathan A.
    Lawo, John-Philip
    Shetty, Harsha
    Pollen, Maressa
    Wieman, Lolis
    Craig, Tim J.
    ALLERGY, 2025, 80 (02) : 545 - 556
  • [7] Integrated safety and efficacy of garadacimab for hereditary angioedema prophylaxis across 3 clinical trials: phase 2, pivotal phase 3, and open- label extension studies
    Magerl, M.
    Craig, T. J.
    Anderson, J.
    Jacobs, J. S.
    Tachdjian, R.
    Farkas, H.
    Yang, W. H.
    Staubach, P.
    Aygoeren-Puersuen, E.
    Ohsawa, I.
    Pollen, M.
    Lawo, J. -P.
    Bica, M. A.
    Jacobs, I.
    ALLERGOLOGIE, 2024, 47 (09)
  • [8] LONG-TERM SAFETY AND EFFICACY WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA PROPHYLAXIS IN AN OPEN- LABEL EXTENSION STUDY
    Anderson, J.
    Levy, D.
    Sussman, G.
    Jacobs, J.
    Farkas, H.
    Pollen, M.
    Feuersenger, H.
    Craig, T.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S5 - S5
  • [9] A phase 3 open-label extension study of the efficacy and safety of lanadelumab for the prevention of angioedema attacks in patients with hereditary angioedema: trial design
    Riedl, M.
    Bernstein, J. A.
    Craig, T.
    Banerji, A.
    Magerl, M.
    Cicardi, M.
    Longhurst, H. J.
    Shennak, M.
    Yang, W.
    Schranz, J.
    Baptista, J.
    Busse, P.
    ALLERGY, 2017, 72 : 598 - 599
  • [10] Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
    Craig, Timothy J.
    Levy, Donald S.
    Reshef, Avner
    Lumry, William R.
    Martinez-Saguer, Inmaculada
    Jacobs, Joshua S.
    Yang, William H.
    Ritchie, Bruce
    Aygoeren-Puersuen, Emel
    Keith, Paul K.
    Busse, Paula
    Feuersenger, Henrike
    Bica, Mihai Alexandru
    Jacobs, Iris
    Pragst, Ingo
    Magerl, Markus
    LANCET HAEMATOLOGY, 2024, 11 (06): : e436 - e447
12345